Grifols 2014 Annual Report on Form 20-F filed with the SEC on April 1, 2015

BARCELONA, Spain, April 1, 2015 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2014 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 1, 2015. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2014.

Form 20-F can be accessed electronically through the Grifols website at http://inversores.grifols.com/en/web/international/sec_filings. The Form 20-F is also available on the SEC's website at http://www.sec.gov.

Grifols will deliver, within a reasonable time after request, a hard copy of the Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request. To request a hard copy, shareholders may contact Grifols by email at [e-mail] to the attention of Grifols' Investor Relations, Re: 2014 Annual Report on Form 20-F.

About Grifols. 75th Anniversary of improving people's health.     
Grifols is a global healthcare company founded in 1940. In 2015 Grifols celebrates its 75th Anniversary of improving people's health and well being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products.

The company is present in more than 100 countries worldwide and is headquartered in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donor centers in the U.S., and a leading producer of plasma-derived biological medicines. The company also provides a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks and transfusion centers, and is a recognized leader in transfusion medicine.

In 2014, sales exceeded Euro 3.3 billion ($4.4 billion) with a headcount close to 14,000 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE: GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/grifols-2014-annual-report-on-form-20-f-filed-with-the-sec-on-april-1-2015-300059194.html

SOURCE Grifols

Copyright 2015 PR Newswire